JP6907227B2 - Ｐｃｖ２ウイルス及びマイコプラズマ・ハイオニューモニエ感染症に対する混合ワクチン - Google Patents
Ｐｃｖ２ウイルス及びマイコプラズマ・ハイオニューモニエ感染症に対する混合ワクチン Download PDFInfo
- Publication number
- JP6907227B2 JP6907227B2 JP2018549447A JP2018549447A JP6907227B2 JP 6907227 B2 JP6907227 B2 JP 6907227B2 JP 2018549447 A JP2018549447 A JP 2018549447A JP 2018549447 A JP2018549447 A JP 2018549447A JP 6907227 B2 JP6907227 B2 JP 6907227B2
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- pcv2
- mycoplasma
- immunogen
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960005486 vaccine Drugs 0.000 title claims description 152
- 241001673669 Porcine circovirus 2 Species 0.000 title claims description 79
- 208000015181 infectious disease Diseases 0.000 title claims description 36
- 241000204031 Mycoplasma Species 0.000 title claims description 27
- 241001465754 Metazoa Species 0.000 claims description 82
- 238000002255 vaccination Methods 0.000 claims description 58
- 230000002163 immunogen Effects 0.000 claims description 38
- 239000002671 adjuvant Substances 0.000 claims description 34
- 230000003362 replicative effect Effects 0.000 claims description 26
- 241000700605 Viruses Species 0.000 claims description 24
- 239000007908 nanoemulsion Substances 0.000 claims description 24
- 241001148567 Lawsonia intracellularis Species 0.000 claims description 15
- 239000002480 mineral oil Substances 0.000 claims description 15
- 235000010446 mineral oil Nutrition 0.000 claims description 15
- 230000002238 attenuated effect Effects 0.000 claims description 11
- 239000000839 emulsion Substances 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 238000011321 prophylaxis Methods 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 claims description 6
- 101710113540 ORF2 protein Proteins 0.000 claims description 6
- 101710090523 Putative movement protein Proteins 0.000 claims description 6
- 230000036039 immunity Effects 0.000 claims description 6
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 claims description 4
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 229940001442 combination vaccine Drugs 0.000 description 26
- 230000004044 response Effects 0.000 description 22
- 238000012360 testing method Methods 0.000 description 21
- 244000052769 pathogen Species 0.000 description 20
- 241000282887 Suidae Species 0.000 description 19
- 230000036541 health Effects 0.000 description 19
- 230000001717 pathogenic effect Effects 0.000 description 19
- 241001135902 Peanut clump virus Species 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 206010024769 Local reaction Diseases 0.000 description 11
- 230000000405 serological effect Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 9
- 230000003902 lesion Effects 0.000 description 8
- 241001469654 Lawsonia <weevil> Species 0.000 description 7
- 241000282898 Sus scrofa Species 0.000 description 7
- 230000036760 body temperature Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 206010058874 Viraemia Diseases 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 238000013401 experimental design Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000004530 micro-emulsion Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000002559 palpation Methods 0.000 description 4
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001842 enterocyte Anatomy 0.000 description 3
- 238000009313 farming Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 101100309717 Arabidopsis thaliana SD22 gene Proteins 0.000 description 2
- 241001292006 Arteriviridae Species 0.000 description 2
- 208000031504 Asymptomatic Infections Diseases 0.000 description 2
- 101000977023 Azospirillum brasilense Uncharacterized 17.8 kDa protein in nodG 5'region Proteins 0.000 description 2
- 101000961984 Bacillus thuringiensis Uncharacterized 30.3 kDa protein Proteins 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 229940032024 DPT vaccine Drugs 0.000 description 2
- 101000644901 Drosophila melanogaster Putative 115 kDa protein in type-1 retrotransposable element R1DM Proteins 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 101000747702 Enterobacteria phage N4 Uncharacterized protein Gp2 Proteins 0.000 description 2
- 101000758599 Escherichia coli Uncharacterized 14.7 kDa protein Proteins 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 101000768930 Lactococcus lactis subsp. cremoris Uncharacterized protein in pepC 5'region Proteins 0.000 description 2
- 241000710788 Lelystad virus Species 0.000 description 2
- 101000976302 Leptospira interrogans Uncharacterized protein in sph 3'region Proteins 0.000 description 2
- 101000778886 Leptospira interrogans serogroup Icterohaemorrhagiae serovar Lai (strain 56601) Uncharacterized protein LA_2151 Proteins 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 101100382437 Porcine circovirus 2 Cap gene Proteins 0.000 description 2
- 101001121571 Rice tungro bacilliform virus (isolate Philippines) Protein P2 Proteins 0.000 description 2
- 101000818098 Spirochaeta aurantia Uncharacterized protein in trpE 3'region Proteins 0.000 description 2
- 101001026590 Streptomyces cinnamonensis Putative polyketide beta-ketoacyl synthase 2 Proteins 0.000 description 2
- 101000750896 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized protein Synpcc7942_2318 Proteins 0.000 description 2
- 101000916321 Xenopus laevis Transposon TX1 uncharacterized 149 kDa protein Proteins 0.000 description 2
- 101000760088 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 20.9 kDa protein Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004081 cilia Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 244000144980 herd Species 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 229940124894 Fluzone Drugs 0.000 description 1
- 229940124877 Fluzone intradermal Drugs 0.000 description 1
- 101000768804 Micromonospora olivasterospora Uncharacterized 10.9 kDa protein in fmrO 5'region Proteins 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 241001292005 Nidovirales Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 1
- 241000202347 Porcine circovirus Species 0.000 description 1
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 244000309457 enveloped RNA virus Species 0.000 description 1
- AVULRCDYZOWVKE-MDZDMXLPSA-N ethyl (e)-octadec-11-en-9-ynoate Chemical compound CCCCCC\C=C\C#CCCCCCCCC(=O)OCC AVULRCDYZOWVKE-MDZDMXLPSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000026526 progressive weakness Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000010686 shark liver oil Substances 0.000 description 1
- 229940069764 shark liver oil Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-AAJYLUCBSA-N squalene group Chemical group CC(C)=CCC\C(\C)=C\CC\C(\C)=C\CC\C=C(/C)\CC\C=C(/C)\CCC=C(C)C YYGNTYWPHWGJRM-AAJYLUCBSA-N 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- UBCKGWBNUIFUST-YHYXMXQVSA-N tetrachlorvinphos Chemical compound COP(=O)(OC)O\C(=C/Cl)C1=CC(Cl)=C(Cl)C=C1Cl UBCKGWBNUIFUST-YHYXMXQVSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229940124856 vaccine component Drugs 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16161997.8 | 2016-03-23 | ||
| EP16161997 | 2016-03-23 | ||
| PCT/EP2017/056831 WO2017162741A1 (en) | 2016-03-23 | 2017-03-22 | A combination vaccine against pcv2 virus and mycoplasma hyopneumoniae infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019509300A JP2019509300A (ja) | 2019-04-04 |
| JP2019509300A5 JP2019509300A5 (enExample) | 2020-03-12 |
| JP6907227B2 true JP6907227B2 (ja) | 2021-07-21 |
Family
ID=55589754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018549447A Expired - Fee Related JP6907227B2 (ja) | 2016-03-23 | 2017-03-22 | Ｐｃｖ２ウイルス及びマイコプラズマ・ハイオニューモニエ感染症に対する混合ワクチン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20190105385A1 (enExample) |
| EP (1) | EP3432919A1 (enExample) |
| JP (1) | JP6907227B2 (enExample) |
| CN (1) | CN108697782A (enExample) |
| BR (1) | BR112018069100A2 (enExample) |
| RU (1) | RU2018137034A (enExample) |
| WO (1) | WO2017162741A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020011044A2 (pt) * | 2017-12-04 | 2020-11-17 | Intervet International B.V. | vacinação com partículas de replicon e adjuvante de óleo |
| JP7510874B2 (ja) * | 2017-12-22 | 2024-07-04 | ヒプラ シエンティフィック エセ．エレ．ウ． | マイコプラズマ及びブタサーコウイルスに対する皮内混合ワクチン |
| US20220323567A1 (en) * | 2019-09-12 | 2022-10-13 | Intervet Inc. | Combination vaccine for intradermal administration |
| EP4138892A1 (en) * | 2020-04-20 | 2023-03-01 | Intervet International B.V. | A vaccine to protect against mycoplasma hyopneumoniae |
| CN115427072A (zh) * | 2020-04-20 | 2022-12-02 | 英特维特国际股份有限公司 | 预防性治疗猪的疫苗组合 |
| WO2025132513A1 (en) | 2023-12-19 | 2025-06-26 | Intervet International B.V. | Low-energy electron irradiation-inactivated mollicutes |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU212924B (en) * | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| JP2006528647A (ja) * | 2003-07-24 | 2006-12-21 | メリアル リミテッド | 新規ワクチン製剤 |
| UA89631C2 (en) * | 2004-04-05 | 2010-02-25 | Пфайзер Продактс Инк. | Vaccine composition |
| ATE462445T1 (de) | 2005-01-13 | 2010-04-15 | Boehringer Ingelheim Vetmed | Prrs-impfstoffe |
| US8834891B2 (en) * | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
| AR054822A1 (es) * | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
| DK1926496T3 (da) | 2005-09-09 | 2013-09-30 | Intervet Int Bv | PCV-2-vaccine |
| DK2371383T3 (en) | 2005-12-29 | 2015-11-30 | Boehringer Ingelheim Vetmed | Use of a PCV2 immunogenic composition for reduction of clinical symptoms in pigs |
| AU2007333857B2 (en) | 2006-12-15 | 2014-05-15 | Boehringer Ingelheim Animal Health USA Inc. | Treatment of pigs with PCV2 antigen |
| TWI449533B (zh) * | 2008-04-18 | 2014-08-21 | Intervet Int Bv | 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗 |
| US8728487B2 (en) | 2011-01-20 | 2014-05-20 | Hua Wu | Attenuated live vaccine for prevention of porcine reproductive and respiratory syndrome |
| CA2848163C (en) * | 2011-09-09 | 2020-10-27 | Nanobio Corporation | Nanoemulsion respiratory syncytial virus (rsv) subunit vaccine |
| UA114504C2 (uk) * | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs |
| UA114503C2 (uk) * | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv та mycoplasma hyopneumoniae |
| US9457073B2 (en) | 2012-09-26 | 2016-10-04 | University Of Manitoba | Live attenuated replication-competent arteriviruses having decreased dub/deisgylating activity |
| CN104043118A (zh) * | 2013-03-11 | 2014-09-17 | 普莱柯生物工程股份有限公司 | 猪prrsv、猪肺炎支原体和pvc-2抗原在制备疫苗中的应用 |
| CN103263666B (zh) * | 2013-05-24 | 2019-07-16 | 北京大北农科技集团股份有限公司动物医学研究中心 | 猪圆环病毒2型、猪支原体肺炎二联灭活疫苗及其制备方法 |
| WO2015082457A1 (en) * | 2013-12-03 | 2015-06-11 | Intervet International B.V. | Vaccine against lawsonia intracellularis and porcine circovirus 2 |
-
2017
- 2017-03-22 RU RU2018137034A patent/RU2018137034A/ru unknown
- 2017-03-22 US US16/086,690 patent/US20190105385A1/en not_active Abandoned
- 2017-03-22 JP JP2018549447A patent/JP6907227B2/ja not_active Expired - Fee Related
- 2017-03-22 BR BR112018069100-3A patent/BR112018069100A2/pt unknown
- 2017-03-22 CN CN201780014561.9A patent/CN108697782A/zh active Pending
- 2017-03-22 EP EP17711241.4A patent/EP3432919A1/en active Pending
- 2017-03-22 WO PCT/EP2017/056831 patent/WO2017162741A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019509300A (ja) | 2019-04-04 |
| BR112018069100A2 (pt) | 2019-01-29 |
| CN108697782A (zh) | 2018-10-23 |
| WO2017162741A1 (en) | 2017-09-28 |
| RU2018137034A (ru) | 2020-04-23 |
| EP3432919A1 (en) | 2019-01-30 |
| RU2018137034A3 (enExample) | 2020-06-26 |
| US20190105385A1 (en) | 2019-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6907227B2 (ja) | Ｐｃｖ２ウイルス及びマイコプラズマ・ハイオニューモニエ感染症に対する混合ワクチン | |
| KR102003620B1 (ko) | Pcv/마이코플라즈마 하이요뉴모니아 조합 백신 | |
| JP6931059B2 (ja) | 豚用混合ワクチン | |
| HRP20140956A2 (hr) | Kombinirano cjepivo protiv pcv, bakterije mycoplasma hyopneumoniae i prrs | |
| HRP20140957A2 (hr) | Cjepivo protiv bakterije mycoplasma hyopneumoniae | |
| JP2023025210A (ja) | 組合せ非混合使用のためのブタ病原体含有ワクチン | |
| JP7558638B2 (ja) | Ｐｃｖ２およびｐｒｒｓウイルス感染に対する皮内適用のためのワクチン | |
| US10953084B2 (en) | Combination vaccine against PCV2 and PRRS virus infection comprising albumin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200130 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210421 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210601 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210630 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6907227 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |